<DOC>
	<DOCNO>NCT00053391</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell mixed tumor protein may make body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness vaccine therapy treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy vaccination autologous dendritic cell pulse tumor influenza antigen peptide treat v without ex vivo CD40-ligand , term tumor-specific T-cell response , patient HLA-A1 and/or HLA-A2.1 positive stage III IV melanoma . - Determine safety tolerability vaccination patient . - Determine tumor response recurrence rate patient treated vaccination . OUTLINE : This open-label non-randomized study . - Phase I : Patients undergo leukapheresis collection peripheral blood mononuclear cell ( PBMC ) . PBMC culture sargramostim ( GM-CSF ) interleukin-4 generate dendritic cell ( DCs ) day -9 . DCs pulse separately HLA-A1 HLA-A2.1-restricted flu matrix peptide derive melanoma-associated tumor antigen ( MAGE-10.A2 , Melan-A , MAGE-3 , NY-ESO-1 , gp100 antigen , tyrosinase peptide ) . Half DCs treat ex vivo CD40-ligand . Patients receive peptide-pulsed DC vaccination subcutaneously ( SC ) day 1 , 14 , 42 , 70 absence disease progression . Patients show tumor response ( least stable disease ) day 98 progress phase II study . - Phase II : Patients undergo leukapheresis phase I day 102 , 352 , 688 . Patients receive 6 additional booster vaccination SC phase I day 126 , 184 , 268 , 356 , 520 , 692 . Patients follow 10 year . PROJECTED ACCRUAL : A total 8-30 patient accrue study within 6-12 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV cutaneous malignant melanoma HLAA1 and/or HLAA2 expression serologic HLA type HLAA2.1 subtype must confirm polymerase chain reaction genomic DNA obtain peripheral blood mononuclear cell No active CNS metastasis CT scan MRI PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 60100 % Life expectancy At least 4 month Hematopoietic WBC great 2,500/mm^3 Neutrophil count great 1,000/mm^3 Lymphocyte count great 700/mm^3 Platelet count great 75,000/mm^3 Hemoglobin great 9 g/dL No bleeding disorder Hepatic Bilirubin le 2.0 mg/dL Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine le 2.5 mg/dL Cardiovascular No clinically significant heart disease Pulmonary No clinically significant respiratory disease Immunologic No active systemic infection No immunodeficiency disease No evidence HIV1 , HIV2 , human Tcell lymphotropic virus1 No active autoimmune disease include ( limited ) : Lupus erythematosus Autoimmune thyroiditis uveitis Multiple sclerosis Inflammatory bowel disease Other Stable medical condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 month study participation No organic brain syndrome psychiatric illness would preclude study compliance No concurrent active malignancy No concurrent serious illness would preclude study treatment No contraindication leukapheresis PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior immunotherapy No concurrent immunotherapy Chemotherapy More 4 week since prior systemic chemotherapy ( 6 week nitrosoureas ) No concurrent chemotherapy Endocrine therapy No concurrent corticosteroid Radiotherapy More 4 week since prior radiotherapy No prior radiotherapy spleen Concurrent palliative radiotherapy allow Surgery Recovered prior surgery No prior splenectomy No prior organ allograft Concurrent surgery select metastasis ( e.g. , pain local complication compression ) allow Other No concurrent investigational drug No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>